Fortress Biotech/FBIO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Fortress Biotech

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Ticker

FBIO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Lindsay Rosenwald

Employees

186

Headquarters

Bay harbor islands, United States

Fortress Biotech Metrics

BasicAdvanced
$37M
Market cap
-
P/E ratio
-$6.65
EPS
1.67
Beta
-
Dividend rate
$37M
1.67079
$10.65
$1.24
219K
1.329
1.208
266.754
279.783
-10.18%
-64.47%
-206.71%
-107.85%
0.431
1.549
10.317
32.48%
58.69%
22.84%

What the Analysts think about Fortress Biotech

Analyst Ratings

Majority rating from 4 analysts.
Buy

Fortress Biotech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-118.46% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-34.67%
Net income
-$15M
67.39%
Profit margin
-118.46%
156.24%

Fortress Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 40.46%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$3.60
-$0.94
-$1.28
-$1.03
-
Expected
-$3.41
-$3.21
-$1.97
-$1.73
-$1.22
Surprise
5.49%
-70.68%
-34.92%
-40.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Fortress Biotech stock?

Fortress Biotech (FBIO) has a market cap of $37M as of June 20, 2024.

What is the P/E ratio for Fortress Biotech stock?

The price to earnings (P/E) ratio for Fortress Biotech (FBIO) stock is 0 as of June 20, 2024.

Does Fortress Biotech stock pay dividends?

No, Fortress Biotech (FBIO) stock does not pay dividends to its shareholders as of June 20, 2024.

When is the next Fortress Biotech dividend payment date?

Fortress Biotech (FBIO) stock does not pay dividends to its shareholders.

What is the beta indicator for Fortress Biotech?

Fortress Biotech (FBIO) has a beta rating of 1.67. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Fortress Biotech stock price target?

The target price for Fortress Biotech (FBIO) stock is $24.75, which is NaN% below the current price of $. This is an average based on projections from 4 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Fortress Biotech stock

Buy or sell Fortress Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing